









Mercado
/
Acciones
/
nasdaq-incy
/

Incyte Corp

INCY

76.320USD

+0.730+0.97%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

14.82BCap. mercado

696.54P/E TTM



Incyte Corp

76.320

+0.730+0.97%

Descripción general Compañía Finanzas

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Información de la empresa

Símbolo de cotizaciónINCY

Nombre de la empresaIncyte Corp

Fecha de salida a bolsaDec 06, 1993

Director ejecutivoMr. Bill Meury

Número de empleados2617

Tipo de seguridadOrdinary Share

Fin del año fiscalDec 06

Dirección1801 Augustine Cut-Off

CiudadWILMINGTON

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal19803

Teléfono13024986700

Sitio Webhttps://www.incyte.com/

Símbolo de cotizaciónINCY

Fecha de salida a bolsaDec 06, 1993

Director ejecutivoMr. Bill Meury

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

Ms. Christiana Stamoulis

Executive Vice President, Chief Financial Officer

263.82K

-1.25%

Mr. Paul J. Clancy

Independent Director

146.88K

+2.00%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Ms. Paula J. Swain

Executive Vice President - Human Resources

106.48K

-0.80%

Mr. Michael James Morrissey

Executive Vice President, Head - Global Technical Operations

86.16K

+5.70%

Dr. Katherine A. High, M.D.

Independent Director

66.08K

+3.96%

Dr. Otis W. Brawley, M.D.

Independent Director

50.10K

+5.29%

Dr. Susanne Schaffert, Ph.D.

Independent Director

37.95K

+4.60%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

Ms. Christiana Stamoulis

Executive Vice President, Chief Financial Officer

263.82K

-1.25%

Mr. Paul J. Clancy

Independent Director

146.88K

+2.00%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Ms. Paula J. Swain

Executive Vice President - Human Resources

106.48K

-0.80%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

JAKAFI revenues

709.41M

67.38%

OPZELURA revenues

118.70M

11.27%

JAKAVI product royalty revenues

92.14M

8.75%

OLUMIANT product royalty revenues

30.80M

2.93%

MINJUVI revenues

29.55M

2.81%

Other

72.28M

6.87%

Sin datos

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

JAKAFI revenues

709.41M

67.38%

OPZELURA revenues

118.70M

11.27%

JAKAVI product royalty revenues

92.14M

8.75%

OLUMIANT product royalty revenues

30.80M

2.93%

MINJUVI revenues

29.55M

2.81%

Other

72.28M

6.87%

Estadísticas de accionistas

Actualizado: sáb., 19 de jul

Accionistas

Tipos de accionistas

Accionistas

Proporción

Baker Bros. Advisors LP

15.61%

The Vanguard Group, Inc.

10.20%

Dodge & Cox

7.61%

BlackRock Institutional Trust Company, N.A.

6.10%

State Street Global Advisors (US)

5.14%

Other

55.34%

Accionistas

Proporción

Baker Bros. Advisors LP

15.61%

The Vanguard Group, Inc.

10.20%

Dodge & Cox

7.61%

BlackRock Institutional Trust Company, N.A.

6.10%

State Street Global Advisors (US)

5.14%

Other

55.34%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

37.07%

Investment Advisor/Hedge Fund

35.74%

Hedge Fund

21.03%

Pension Fund

3.11%

Individual Investor

2.16%

Research Firm

1.99%

Bank and Trust

1.17%

Sovereign Wealth Fund

1.00%

Venture Capital

0.22%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

1417

201.03M

102.93%

+1.34M

2025Q1

1457

199.01M

102.81%

-12.15M

2024Q4

1448

191.80M

99.11%

-19.23M

2024Q3

1401

192.85M

100.02%

-35.92M

2024Q2

1385

209.06M

108.78%

-39.98M

2024Q1

1357

227.85M

101.54%

-21.15M

2023Q4

1323

228.89M

102.19%

-14.49M

2023Q3

1300

224.25M

100.13%

-17.63M

2023Q2

1306

220.30M

98.76%

-17.67M

2023Q1

1294

227.74M

102.15%

-615.23K

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Baker Bros. Advisors LP

30.49M

15.75%

+984.00

+0.00%

Jun 30, 2025

The Vanguard Group, Inc.

19.91M

10.29%

+403.13K

+2.07%

Mar 31, 2025

Dodge & Cox

14.86M

7.68%

-55.30K

-0.37%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

11.92M

6.16%

+257.27K

+2.21%

Mar 31, 2025

State Street Global Advisors (US)

10.04M

5.18%

+4.32K

+0.04%

Mar 31, 2025

AQR Capital Management, LLC

6.74M

3.48%

+3.23M

+92.31%

Mar 31, 2025

Geode Capital Management, L.L.C.

4.21M

2.17%

+167.91K

+4.16%

Mar 31, 2025

Renaissance Technologies LLC

3.71M

1.92%

-377.20K

-9.23%

Mar 31, 2025

LSV Asset Management

3.64M

1.88%

+170.48K

+4.92%

Mar 31, 2025

Invesco Capital Management LLC

2.74M

1.42%

+98.11K

+3.71%

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 2 de ago

Nombre

Proporción

iShares Genomics Immunology and Healthcare ETF

4.03%

First Trust NYSE Arca Biotechnology Index Fund

3.76%

Invesco Biotechnology & Genome ETF

2.77%

SPDR S&P Biotech ETF

2.41%

Bushido Capital US Equity ETF

2.11%

VanEck Biotech ETF

2.07%

Strategas Global Policy Opportunities ETF

1.91%

Virtus LifeSci Biotech Products ETF

1.9%

Invesco S&P 500 Equal Weight Health Care ETF

1.64%

ROBO Global Healthcare Technology & Innovation ETF

1.6%

iShares Genomics Immunology and Healthcare ETF

Proporción4.03%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.76%

Invesco Biotechnology & Genome ETF

Proporción2.77%

SPDR S&P Biotech ETF

Proporción2.41%

Bushido Capital US Equity ETF

Proporción2.11%

VanEck Biotech ETF

Proporción2.07%

Strategas Global Policy Opportunities ETF

Proporción1.91%

Virtus LifeSci Biotech Products ETF

Proporción1.9%

Invesco S&P 500 Equal Weight Health Care ETF

Proporción1.64%

ROBO Global Healthcare Technology & Innovation ETF

Proporción1.6%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

